Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
By Phase
29 drugs in development
By Therapeutic Area
top 6
R&D Momentum
81/100
Pipeline Velocity
36/100
Trial Completion Rate
71/100
Pipeline Concentration
58/100
Pipeline Freshness
53/100
Strategic Signals
Activity
Last 14 days
Pilot Study to Assess the Efficacy of Aspirin to Improve Immunological Features of Ovarian Tumors
Phase 2 Trial With a Safety Run-in of Combinatorial Therapies With Intrathecal (IT) Dendritic Cell Vaccines (cDC1s) inHER+ (Combined With IT Trastuzumab) and HER2- (Combined With IT Nivolumab) Breast Cancer (BC) Leptomeningeal Disease (LMD)
Creation of an Infrastructure to Support Delivery of mHealth Interventions for Cancer Patients Throughout Florida
Evaluation of Digoxin for Relapsed Non-WNT, Non-SHH Medulloblastoma
Prospective Trial to Assess Real-world Outcomes and Predictive Biomarkers of Response to Pembrolizumab With or Without Chemotherapy in Black Patients With NSCLC
Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes
Phase II Study of Systemic Screening in Pathologic Node Positive Breast Cancer Following Neoadjuvant Chemotherapy and Surgery
Support Through Remote Observation and Nutrition Guidance Program for Individuals With Pancreatic Cancer Undergoing Surgery (STRONG-PCS)
Phase 2 Study of Afatinib in Advanced Cutaneous Squamous Cell Carcinoma
Efficacy of a Mindfulness-Based Stress Management Program for Allogeneic HCT Caregivers
Coordinated High Dose Interleukin-2 (Aldesleukin, Proleukin™) and Pembrolizumab (Anti-PD1, Keytruda™) for Therapy of Metastatic Kidney Cancer
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Pipeline
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)